Currently Enrolling Trials


  • KalVista KVD001-201 – A randomized sham-controlled double-masked Phase 2a study of the efficacy, safety and tolerability of the intravitreal plasma kallikrein inhibitor, KVD001, in subjects with center-involving diabetic macular edema who had prior anti-vascular endothelial growth factor treatment

    For more information please email:
    ladams@retinasanantonio.com, vmartinez@retinasanantonio.com or scloudt@retinasanantonio.com





Upcoming Trials









Clinical trials that are completed or closed to new enrollment